Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
DLX6-AS1
Specific or universal ncRNAs
Specific ncRNAs
Class
Long noncoding RNA
Biomarker
None
Biomarker application
Upstream regulatory factors
Not available
Downstream target
Mir-199b-5p/Paxillin
Cancer name
Triple-Negative Breast Cancer
Cancer site
qRT-PCR,Western blot,Luciferase assay
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Up
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis
Tissue resource
tumor tissues and adjacent normal tissues
human breast fibroblast cell lines CCD-1095Sk
human triple-negative breast cancer cell lines HCC1599
human triple-negative breast cancer cell lines MDA-MB-231
human triple-negative breast cancer cell lines HCC1806
human triple-negative breast cancer cell lines HS578T
Experiment
None
Institute
First Affiliated Hospital of Zhengzhou University
American Type Culture Collection
Country
China
United States
Continent
Asia
North Amercian
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.